EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri iD, Francesca Zimetti iD und 1 weitere

ChemMedChem · 2026

DOI: 10.1002/cmdc.202500651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Lisa Giannessi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze degli Alimenti e del Farmaco (DipALIFAR), Università degli Studi di Parma, Viale delle Scienze 27/A, 43124, Parma, Italy. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Pyridones, Proprotein Convertase 9. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia‐related diseases. A new class of small‐molecule inhibitors of PCSK9 transcription, characterized by a 4‐amino‐2‐pyridone scaffold, has been recently identified by our research group. Among them, the early lead compound 5c shows high in vitro potency and favorable in vivo tolerability. However, given the suboptimal in vitro metabolic stability of 5c , its optimization is reported herein by modification of the predicted metabolic soft spots through chemistry‐driven late‐stage functionalization (LSF) strategies. Microsomal stability on the newly synthesized derivatives allows drawing structure–metabolism relationships (SMRs) that, coupled with a thorough pharmacological investigation on HepG2 cells, leads to the identification of novel C3‐ and dual C3/NHC4‐functionalized pyridones with improved stability and superior pharmacological profiles. Notably, compounds 6b , 7 , and 18a emerge as the best candidates, demonstrating markedly improved metabolic stability/PCSK9 IC 50 ratio and comparable or lower cytotoxicity with respect to the parent compound 5c . These findings underscore the value of LSF strategies in generating optimized analogs of 5c with strong potential for further preclinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsPyridonesProprotein Convertase 9HumansStructure-Activity RelationshipHep G2 CellsMolecular StructureDose-Response Relationship, DrugCell Survival

Stichwörter der Autor:innen

PCSK9green chemistryproprotein convertase subtilisin/kexin type 9pyridonessmall moleculesstructure–metabolism relationship

Substanzen

PCSK9 InhibitorsPyridonesProprotein Convertase 9PCSK9 protein, human

Autor:innen und Institutionen

  • Dipartimento di Scienze degli Alimenti e del Farmaco (DipALIFAR), Università degli Studi di Parma, Viale delle Scienze 27/A, 43124, Parma, Italy.
  • Department of Medicine, University of Padova, 35128, Padova, Italy.

ORCID-Profile: Nicola Ferri, Francesca Zimetti, Marco Radi

Zitieren

APA

Giannessi, L., Lupo, M. G., Ugolotti, M., Papotti, B., Mattina, B., Martina, M. G., Demurtas, A., Padula, C., Nicoli, S., Crescenzio, M., Ferri, N., Zimetti, F., & Radi, M. (2026). Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships. ChemMedChem. https://doi.org/10.1002/cmdc.202500651

Vancouver

Giannessi L, Lupo MG, Ugolotti M, Papotti B, Mattina B, Martina MG, et al. Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships. ChemMedChem. 2026. doi:10.1002/cmdc.202500651

BibTeX
@article{Giannessi2026,
  author = {Giannessi, Lisa and Lupo, Maria Giovanna and Ugolotti, Martina and Papotti, Bianca and Mattina, Beatrice and Martina, Maria Grazia and Demurtas, Anna and Padula, Cristina and Nicoli, Sara and Crescenzio, Marco and Ferri, Nicola and Zimetti, Francesca and Radi, Marco},
  title = {Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202500651}
}
Kostenlos starten →